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be more important in the future. Although responents re-
ported their knowledge of pharmacoeconomics to be
good, a substantial lack of interest in caregiver burden
suggests that a large percentage of MCOs are still in a
silo model.
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Stadtlanders Pharmacy focuses on the management of
high-cost, chronic illnesses by targeting numerous medi-
cation-optimizing initiatives towards patients and pre-
scribers. The cost impact of these initiatives has never
been measured in a controlled fashion. PURPOSE: The
purpose of this study is to assess the impact of an exclu-
sive pharmacy provider contract with a large HMO on
healthcare expenditures by a third party payor. This
analysis will evaluate per member per month (PMPM)
medical costs based on claims data prior to and following
a National Agreement that mandates exclusive pharmacy
services for HIV and transplant patients. METHODS: A
retrospective analysis of medical claims data was per-
formed for 40 patients from selected plans of a large, na-
tionwide HMO. Time frame for the analysis was 6
months prior to (1/97 to 6/97) and 6 months following
(1/98 to 6/98) an exclusive provider relationship with
Stadtlanders Pharmacy and the HMO. Inclusion criteria
consisted of transplant and HIV1 patients enrolled in the
third party plan from 1/97 to 6/98, who received immun-
osuppressants and antiretrovirals, respectively, from
Stadtlanders during the post-agreement time frame. Med-
ical claim submissions during the specified time periods
were analyzed to determine mean per-member-per-month
(PMPM) values. RESULTS: Nineteen transplant and 21
HIV patients were included in the analysis. Mean medical
PMPM prior to and following the National agreement
was $053 and $911, respectively for transplant patients
and $448 and $306, respectively for HIV patients. The
mean overall saving in medical costs was approximately
$140 PMPM for each disease state following the exclu-
sive contract with Stadtlanders Pharmacy. CONCLU-
SION: This analysis represents potential overall health-
care savings for certain chronic illnesses through an
exclusive partnership between a specialty pharmacy and
an HMO.
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OBJECTIVE: We assessed the usefulness of the French
hospital database (PMSI) implemented in view of a DRG-
like prospective payment system for an economic evaluation
of the management of haemophiliac patients. METH-
ODS: We extracted and analysed data of the French pub-
lic hospital database on hospitalizations with a principal
or secondary diagnosis of haemophilia (type A) for the
years 1996–1997. RESULTS: A total number of 7000
admissions were found per year. The inpatient admis-
sions concerned haematology and orthopaedic surgery
but were scattered over a total number of 328 DRGs, re-
flecting both the variability of practice patterns and more
likely of coding procedures. Almost all of DRGs have less
than 1% of the files registered. We identified 3 main am-
bulatory DRGs but none was specific to haemophilia.
The ambulatory DRGs contain more than 50% of the
files related to haemophilia. The analysis of the national
database does not permit to identify neither the type of
therapeutic strategy for haemophilia (prophylactic treat-
ment or on demand treatment) nor the presence of a factor
VIII inhibitor. We found differences on the quality of diag-
nostic coding between the regional university hospitals
(UH) and the local hospitals. The mean of diagnostics reg-
istered for patients in 1997 is 2.9 diagnostics in UH and 4
in other hospitals. We compared the observed costs of hae-
mophiliac patients with the DRG reimbursement schedule
and found variations from plus to minus 40%. This gap is
mainly explained by the length of hospitalization. Thus it
appeared that the national DRG database is not currently
appropriate for assessing the management and costs of
treatments for haemophiliac patients, but could well sup-
plement the existing prospective cohort studies.
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The impact of patient compliance/adherence on disease
management is well known. In order to improve compli-
ance with medication regimens health care providers
have counted pills, evaluated re-fill patterns, developed
electronic devices, used questionnaires to identify prob-
lem areas, yet compliance remains a significant barrier to
the effectiveness of medication regimens. OBJECTIVE:
